Jefferies upgrades Zydus Life to ‘Buy’ on strong US pipeline potential, stock up 4%
Global brokerage firm Jefferies has upgraded Zydus Lifesciences to a ‘Buy’ rating, citing the strength of the companyβs US pipeline as a key driver for future growth. The brokerage raised its target price for the stock to Rs 1,450 from the previous Rs 1,210, reflecting a 30% upside potential from the previous day’s closing price…
READ MORE